Invasive fungal disease (IFD)
IFDs, IFD
ADVERSE EVENTS
Serious adverse events (SAEs) were prospectively captured and reported by the participating institutions. According to study guidelines, IFDs were considered as SAEs, thus, reporting was mandatory. All SAE reports were reviewed and classified by the safety desk of the clinical trial office in Germany (AM/JA), and all SAEs suggestive for IFD were independently reviewed by two experts (TL/AHG). Children were categorized with proven, probable, possible or no IFD according to the revised and updated consensus definitions elaborated by the European Organisation for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [